DIAGENS-B Moves to Update Articles of Association After IPO and Regulatory Changes

Bulletin Express04-29

Hangzhou Diagens Biotechnology Co., Ltd. (DIAGENS-B) has announced a plan to revise its Articles of Association following two significant developments: the March 2025 update of the China Securities Regulatory Commission’s (CSRC) Guidelines for the Articles of Association of Listed Companies and the company’s Hong Kong Main Board listing completed on 30 March 2026.

The board resolved on 29 April 2026 to propose a package of amendments designed to align the company’s governing document with the latest regulatory requirements and its new capital structure. Key context includes:

• Capital structure shift: DIAGENS-B issued 7.99 million H shares (RMB1.00 nominal value each) in its initial public offering and simultaneously converted all previous unlisted shares into H shares. Post-offering, total share capital stands at 88.88 million H shares.

• Governance alignment: The revisions will incorporate the CSRC’s 2025 guideline updates and add “housekeeping” changes aimed at enhancing corporate governance.

The proposed amendments require approval via special resolution at the forthcoming annual general meeting. A circular detailing the changes will be distributed to shareholders in due course.

As of the announcement date, the board comprises two executive directors (Dr. Song Ning and Mr. Weng Chih-Hsin), three non-executive directors (Dr. Xu Chen, Dr. Wu Lingqian and Mr. Yang Zehao) and three independent non-executive directors (Mr. Cha Yang, Ms. Zhang Jing and Mr. Wang Kaifeng).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1181077977?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-29 17:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181077977","market":"us","top_or_hot":-1,"title":"DIAGENS-B Moves to Update Articles of Association After IPO and Regulatory Changes","media":"Bulletin Express","content":"<p>Hangzhou Diagens Biotechnology Co., Ltd. (DIAGENS-B) has announced a plan to revise its Articles of Association following two significant developments: the March 2025 update of the China Securities Regulatory Commission’s (CSRC) Guidelines for the Articles of Association of Listed Companies and the company’s Hong Kong Main Board listing completed on 30 March 2026.</p>\n<p>The board resolved on 29 April 2026 to propose a package of amendments designed to align the company’s governing document with the latest regulatory requirements and its new capital structure. Key context includes:</p>\n<p>• Capital structure shift: DIAGENS-B issued 7.99 million H shares (RMB1.00 nominal value each) in its initial public offering and simultaneously converted all previous unlisted shares into H shares. Post-offering, total share capital stands at 88.88 million H shares.</p>\n<p>• Governance alignment: The revisions will incorporate the CSRC’s 2025 guideline updates and add “housekeeping” changes aimed at enhancing corporate governance.</p>\n<p>The proposed amendments require approval via special resolution at the forthcoming annual general meeting. A circular detailing the changes will be distributed to shareholders in due course.</p>\n<p>As of the announcement date, the board comprises two executive directors (Dr. Song Ning and Mr. Weng Chih-Hsin), three non-executive directors (Dr. Xu Chen, Dr. Wu Lingqian and Mr. Yang Zehao) and three independent non-executive directors (Mr. Cha Yang, Ms. Zhang Jing and Mr. Wang Kaifeng).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DIAGENS-B Moves to Update Articles of Association After IPO and Regulatory Changes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDIAGENS-B Moves to Update Articles of Association After IPO and Regulatory Changes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-29 17:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hangzhou Diagens Biotechnology Co., Ltd. (DIAGENS-B) has announced a plan to revise its Articles of Association following two significant developments: the March 2025 update of the China Securities Regulatory Commission’s (CSRC) Guidelines for the Articles of Association of Listed Companies and the company’s Hong Kong Main Board listing completed on 30 March 2026.</p>\n<p>The board resolved on 29 April 2026 to propose a package of amendments designed to align the company’s governing document with the latest regulatory requirements and its new capital structure. Key context includes:</p>\n<p>• Capital structure shift: DIAGENS-B issued 7.99 million H shares (RMB1.00 nominal value each) in its initial public offering and simultaneously converted all previous unlisted shares into H shares. Post-offering, total share capital stands at 88.88 million H shares.</p>\n<p>• Governance alignment: The revisions will incorporate the CSRC’s 2025 guideline updates and add “housekeeping” changes aimed at enhancing corporate governance.</p>\n<p>The proposed amendments require approval via special resolution at the forthcoming annual general meeting. A circular detailing the changes will be distributed to shareholders in due course.</p>\n<p>As of the announcement date, the board comprises two executive directors (Dr. Song Ning and Mr. Weng Chih-Hsin), three non-executive directors (Dr. Xu Chen, Dr. Wu Lingqian and Mr. Yang Zehao) and three independent non-executive directors (Mr. Cha Yang, Ms. Zhang Jing and Mr. Wang Kaifeng).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02526","symbol_name":"德适-B","start_time":0,"source_url":"","article_id":"1181077977","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181077977","pubTimestamp":1777453603,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hangzhou Diagens Biotechnology Co., Ltd. (DIAGENS-B) has announced a plan to revise its Articles of Association following two significant developments: the March 2025 update of the China Securities...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02526":"德适-B"},"translate_title":"DIAGENS-B在IPO和监管变化后更新公司章程","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02526":1},"content_text":"Hangzhou Diagens Biotechnology Co., Ltd. (DIAGENS-B) has announced a plan to revise its Articles of Association following two significant developments: the March 2025 update of the China Securities Regulatory Commission’s (CSRC) Guidelines for the Articles of Association of Listed Companies and the company’s Hong Kong Main Board listing completed on 30 March 2026.\nThe board resolved on 29 April 2026 to propose a package of amendments designed to align the company’s governing document with the latest regulatory requirements and its new capital structure. Key context includes:\n• Capital structure shift: DIAGENS-B issued 7.99 million H shares (RMB1.00 nominal value each) in its initial public offering and simultaneously converted all previous unlisted shares into H shares. Post-offering, total share capital stands at 88.88 million H shares.\n• Governance alignment: The revisions will incorporate the CSRC’s 2025 guideline updates and add “housekeeping” changes aimed at enhancing corporate governance.\nThe proposed amendments require approval via special resolution at the forthcoming annual general meeting. A circular detailing the changes will be distributed to shareholders in due course.\nAs of the announcement date, the board comprises two executive directors (Dr. Song Ning and Mr. Weng Chih-Hsin), three non-executive directors (Dr. Xu Chen, Dr. Wu Lingqian and Mr. Yang Zehao) and three independent non-executive directors (Mr. Cha Yang, Ms. Zhang Jing and Mr. Wang Kaifeng).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1181077977","isCrawlerRequest":true}